Epstein Secrets

o: Jefffrey Epstein <[email protected]>, Rich Kahn < Subject: Date: Thu, 17 Jan 2019 17:19:49 +000

From: Lesley Groff To: Jefffrey Epstein <[email protected]>, Rich Kahn < Subject: Date: Thu, 17 Jan 2019 17:19:49 +0000 Inline-Images: 1506365439123blobjpg; 1506365439123blob(1).jpg > equested I forward you the belo

ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the US

From: Richard Kahn To: EM IES Subject: Re: Date: Thu, 17 Jan 2019 22:20:11 +0000 i asked JEE and he said to ignore so no need to follow up with jee.. thanks Richar

From: Richard Kahn To: EM IES Subject: Re: Date: Thu, 17 Jan 2019

ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the U

From: To: Rich Kahn Subject: Re: Date: Thu, 17 Jan 2019 22:20:51 +0000 got it! thanks On Jan 17, 2019, at 5:20 PM, Richard Kahn wrote: i asked JEE and he said to ignore so no need to follow up with jee.. thanks Richard Kahn MO= tel fax cell On Jan 17, 2019, at 4:04

From: To: Rich Kahn Subject: Re: Date: Thu, 17 Jan 2019 22:20:51 +0

ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the U

o: Jefffrey Epstein[[email protected]]; Rich Kahn From: Lesley Groff Sent: Thur 1/17/2019 5:19:

To: Jefffrey Epstein[[email protected]]; Rich Kahn From: Lesley Groff Sent: Thur 1/17/2019 5:19:49 PM Subject: Fo From: < r t oksjaySsam a > To: jeevacation@gmaitcom <jeevacationeinmait.c

ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that EFTA_R1_01089814 EFTA02275773 reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly

To: Lesley Groff( From: Richard Kahn Sent subsa Thu PM . Re: i will mention to jee when we speak next thanks Richard Kahn HBRK Associates Inc. 575 Lexington Avenue 4th Floor N

To: Lesley Groff( From: Richard Kahn Sent subsa Thu PM . Re: i will mention to j

cal industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the U

To: Richard Kahn From: Lesley Groff Subject ThuWWI PM Re: I I Thx Sent from my iPhone On Jan 17, 2019, at 3:50 PM, Richard Kahn <richardkahn I [email protected]>

To: Richard Kahn From: Lesley Groff Subject ThuWWI PM Re: I

cal industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the ncuroglobin gene) under formal licence review with a publicly traded pharma group here in the

From: Lesley Groff <-> Sent: Thursday, January 17, 2019 5:20 PM To: Jefffrey Epstein; Rich Kahn Subject: requested I forward you the below 'catch =p' email. = cell: <=ont =d="ydp10b69158yiv1803357833ydpcb0f5alfyiv3847271241ydp49348eceyiv83

ary 17, 2019 5:20 PM To: Jefffrey Epstein; Rich Kahn Subject: requested I forward you the below 'cat

ical industry to shift their focus from addressing =ymptoms of disease to fundamental evolutionary shortfalls. So far, I placed a =enetic vector at the National Institute of Medicine in France (that =eversed glaucoma in mice using the neuroglobin gene) under formal =icence review with a publicly traded pharma group here in the US